Streptococcus pneumoniae serotype 5

Streptococcus pneumoniae serotype 5 is a specific variant of the encapsulated Gram-positive bacterium S. pneumoniae distinguished by its unique capsular polysaccharide structure. This serotype is globally significant due to its association with outbreaks and invasive pneumococcal diseases such as pneumonia, bacteremia, and meningitis. Serotype 5 exhibits hypervirulent features—while it has low carriage rates in healthy populations compared to other serotypes, it demonstrates high transmission potential during epidemics. Molecular epidemiology studies have identified several sequence types within this serotype; ST289 is predominant worldwide and linked with multidrug resistance profiles in some regions. The primary virulence factor for all S. pneumoniae strains—including serotype 5—is the capsule composed of repeating oligosaccharides that protect against phagocytosis by host immune cells. Serotype-specific immunity can be induced through vaccination targeting its capsule; these vaccines are effective at preventing disease caused by this organism but do not directly target a molecular receptor or enzyme typical for drug targets. While antibiotics remain effective against most isolates—especially beta-lactams like penicillin—there are increasing reports of resistance to other agents such as co-trimoxazole and tetracycline depending on geographic region. Streptococcus pneumoniae serotype 5 should be considered an infectious agent rather than a classical therapeutic "target" like an enzyme or receptor; thus it does not fit standard definitions used for drug discovery targets.

Other names

S. pneumoniae serotype 5Pneumococcus serotype 5Streptococcus pneumoniae type 5

Antibiotics inhibit cell wall synthesis or protein synthesis in bacteria. Vaccines induce production of antibodies against the capsular polysaccharide to promote opsonization and clearance by the immune system.